Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avillion LLP
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
The US Food and Drug Administration has approved AstraZeneca and Avillion’s respiratory drug Airsupra, making it the only rescue medication cleared for as-needed use to reduce risk of asthma exacerbations.
In near unanimous votes, advisory committee rejects budesonide/albuterol sulfate fixed-dose combination for young children but favors approval for adults; the vote in adolescents was more divided, with some panelists believing extrapolation of adult efficacy data were appropriate for this population.
US FDA is asking an advisory committee whether extrapolation of adult data is appropriate to bridge uncertainties in efficacy for asthma patients under age 18 years; metered-dose inhaler would be the first combination product approved in the US containing an inhaled corticosteroid and a short-acting beta2-adrenergic agonist.
- Other Names / Subsidiaries
- Avillion Group
- Bond Avillion 2 Development LP
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.